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TO THE EDITOR
Skin pigmentation disorders are among
the most recognizable human diseases,
strongly impacting both health and qual-
ity of life. Lentigines are small, hyper-
pigmented skin macules, histologically
containing increased numbers of mela-
nocytes, typically producing elevated
amounts of melanin. Most lentigines
are caused by UV radiation and appear
with increasing age. However, lentigines
can also be inherited in an autosomal
dominant pattern; in these cases, lenti-
gines typically appear in childhood (see
review Bauer and Stratakis, 2005). We
previously reported autosomal dominant
inheritance of a unique lentiginous pig-
mentation disorder (Pacheco et al., 2002,
2004). Here, we report identiﬁcation of a
variant associated with this lentiginous
phenotype in the SASH1 gene, with
additional histological analysis of the
patients’ skin. All blood samples,
biopsies, photographs, and information
from subjects obtained after written
informed patient consent were approved
by the relevant institutional review boards
(including permission to publish images).
Our previous linkage analysis of this
family mapped the disease locus to a
10-Mb interval between 6q24.2-q25.2
(Pacheco et al., 2002, 2004). Linkage
analyses of two Chinese families also
mapped a similar pigmentation disorder
to the same region (Xing et al., 2003).
The overlapping linkage interval of
these three families is ﬂanked by
markers D6S1703 and D6S441.
In the current family, candidate genes
within the linkage interval were screened
for mutations, including all exons, 100 bp
of introns, and 2 kb of the ﬂanking
promoter region. DNA sequence analysis
of 17 affected and 18 unaffected family
members identiﬁed a heterozygous
missense substitution in SASH1, in exon
13, c.1556 G-4A, p. S519N (Figure 1a
and b). This variant was the only one that
co-segregated perfectly with disease,
and was not observed in 150 ethnically
matched normal controls, 20 melanoma
patients with lentigines, or in the UCSC
Genome, Ensembl, HapMap, NCBI
dbSNP, or the Japanese SNP variant
databases.
All affected family members exhibited a
similar phenotype of dark brown macules
of lentigines (Figure 1c and d), typically
presenting in the ﬁrst decade of life, most
prominent in sun-exposed areas. In some
cases, lentigines covered the face, trunk,
and extremities, and in other case,
occurred principally over the face and
distal extremities (Figure 1c and d).
The diagnosis of lentigines is based on
the presence of increased melanin pig-
mentation, higher density of melanocytes,
and characteristic elongation of rete ridges
—the inward projections of the epidermis
into the dermis (Figure 2a) (Montagna
et al., 1980). Tissue sections stained with
the melanocyte marker MART1 showed
an ~2-fold increase in melanocyte
number per mm of skin biopsy in both
the hyper-pigmented lesional and adja-
cent non-lesional skin of affected patients
(Figure 2). However, only lesional skin
has a dramatic increase in melanin
(Figure 2a). Sections stained with the
proliferation marker, Ki67, showed that
patients had ~2-fold more proliferating
cells in both lesional and non-lesionalAccepted article preview online 23 July 2015; published online 13 August 2015
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skin (Figure 2c and d). These ﬁndings
indicate that the S519N SASH1 substitu-
tion increased the number of melanocytes
and epidermal cell proliferation in skin.
SASH1 encodes a signal adaptor
protein of 1,230 amino acids that con-
tains two nuclear localization signals, a
SLY domain, a SH3 domain, and two
SAM domains. The S519N substitution is
located in the highly conserved SLY
domain. SASH1 is expressed in many
human tissues, including whole skin,
keratinocytes, ﬁbroblasts, and melano-
cytes (NCBI Gene Expression Omnibus;
http://www.ncbi.nlm.nih.gov/geo/). We
also detected SASH1 expression in
cultured human epidermal keratino-
cytes, dermal ﬁbroblasts, and melano-
cytes (Supplementary Figure 1 online).
The function of SASH1 is unknown.
Reduced SASH1 expression has been
associated with tumor progression in
breast and colon cancers, suggesting
that it is a candidate tumor suppressor
(Zeller et al., 2003; Rimkus et al., 2006).
Other studies present conﬂicting ﬁndings.
In vitro studies of various cancer cells
indicate that SASH1 may inhibit cancer
cell survival, proliferation, migration, or
invasion (Martini et al., 2011; Chen et al.,
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Figure 2. Histological examination indicates a lentiginous phenotype in the skin from affected individuals. (a) The images of immuno-histochemistry
staining with the melanocyte marker (MART1 in red) for the skin biopsies were collected from non-photoexposed skin of ventral forearms of an unaffected
individual, and from lesional (hyper-pigmented area) and adjacent non-lesional area (1 cm or more distant normal-appearing skin) tissue from the same
affected patient. Scale bar=50 μm. The upper, epidermal layer is indicated by “E”, the lower dermal layer is denoted “D”, and the arrow points to the
rete ridges. (b) The same skin biopsies as in (a) were double-stained with antibodies to the melanocyte marker, MART1 (green), and the proliferation antigen,
Ki67 (red). Scale bar=50 μm. The quantiﬁcation of the MART1 (c) or Ki67 (d) staining in (b) was performed by counting the number of positively stained
cells per millimeter of tissue across the entire length of the tissue biopsy. Three affected patients and three unaffected siblings were biopsied. Panel (c) shows
a greater than two-fold increase in MART1 staining in the skin for all affected patients as compared with controls, and panel (d) shows about two-fold increase in
Ki67 staining in the skin for all affected patients as compared with controls. Increased proliferation was also apparent in affected patients in non-lentiginous areas.
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Figure 1. Identiﬁcation of SASH1S519N in an inherited lentiginosis. (a) Sequence chromatograms of an
unaffected and an affected individual, with a heterozygous point mutation in the SASH1 gene (c. 1556G-
4A) in the affected individual. (b) The regular view (left panels) and melanin pigmentation view of facial
images (right panels) from indicated individuals. Images were captured with a VISIA-Complexion Analysis
(VISIA-CA) multi-modality facial imaging system. (c) The regular view of hands from an affected
individual.
YG Shellman et al.
SASH1 in a Hyper-Pigmentation Disorder
www.jidonline.org 3193
2012; Lin et al., 2012; Yang et al., 2012;
Meng et al., 2013; Zhou et al., 2013),
whereas a study with a non-pigmented
metastatic melanoma cell line suggests
that SASH1 may increase cell migration
(Zhou et al., 2013). Furthermore, in
human endothelial cells SASH1 may act
as a scaffold molecule in Toll-Like Recep-
tor signaling in the innate immune
response (Dauphinee et al., 2013). Thus,
SASH1 may have speciﬁc but different
functions in different cell types.
Recently, another missense substitu-
tion of SASH1 (c.1849G-4A; p.E617K)
was found to be associated with a
genodermatosis in an autosomal reces-
sive manner, which included hyper-
pigmented macules on the trunk, face,
and extremities, with some similarity
to our patients (Courcet et al., 2015).
Moreover, a non-peer-reviewed study,
deposited at Nature Precedings (2011),
reported three additional variants in
SASH1 (E509K, L515P, and Y551D)
associated with a pigmentation disorder
in three Chinese families. Taken
together, SASH1 thus appears to be a
gene involved in regulation of human
skin pigmentation and SASH1 variants
may cause autosomal-dominant or
-recessive genodermatosis.
Other genes associated with familial
lentiginosis encode important signaling
proteins such as RAF1, BRAF, SOS,
SHP2, PTEN, LKB1, and PKA (see review
Bauer and Stratakis, 2005). The identiﬁ-
cation of SASH1 as an additional gene
involved in familial lentigines provides
fresh insights into the development of
hyper-pigmentation in human skin.
Further examination of the roles of
SASH1 in normal skin is needed to
understand the molecular mechanisms
affected. A combination of in vitro
studies with human cells and in vivo
studies with animal models are needed
to better deﬁne SASH1’s function in skin.
These investigations will determine
whether SASH1 regulates or interacts
with known pathways involved in hyper-
pigmentation disorders, and determine
SASH1’s function in development, dif-
ferentiation, proliferation, survival, and
cell migration of skin cells.
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